Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Biobizkaia Health Research Institute
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07448285CT.gov Clinical Trial to Evaluate the Efficacy and Safety of Platelet-rich Plasma Infiltration in Chronic Omalgia | — | Recruiting | — | — | — |
NCT06617065CT.gov Exploring Long-term Pain Relief with 5% Dextrose Added to Local Anesthetic | — | Active Not Recruiting | — | — | — |
NCT05843344CT.gov Dexmedetomidine and Morphine as Adjuvants to US Guided Erector Spinae Plane Blocks in Elective Thoracic Surgeries | — | Unknown | — | — | — |
NCT04313959CT.gov Comparison Erect Spine in Cardiac Surgery | — | Unknown | — | — | — |
NCT05175001CT.gov Efficacy of Compound Betamethasone Injection Combined With Ropivacaine in Ultrasound-guided Thoracic Paravertebral Nerve Block for Chronic Post-thoracotomy Pain | — | Unknown | — | — | — |
NCT04852484CT.gov Morphine Versus Ketamine as Adjuvants in Paravertebral Blocks | — | Unknown | — | — | — |
NCT02460640CT.gov The Effects of TAP Block on Postsurgical Pain After Minimally Invasive Partial Nephrectomy: | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Pain Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ropivacaine (this asset) | Biobizkaia Health Research Institute | Approved | BB · 64 |
| (±)-Tramadol | EMS | P4 | BBB |
| Methadone | Cari Health Inc. | P4 | BBB |
| Lidocaine | National and Kapodistrian University of Athens | P4 | BBB |
| Nepenthe | Bursa City Hospital | P4 | BBB |
| Fentanyl | Aga Khan University | P4 | BBB |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | Stanford University | P4 | BBB |
| Jnj-54135419 | Beijing Tiantan Hospital | P4 | BBB |
| Pregabalin | Federico II University | P4 | BBB |
+42 more in the Chronic Pain Syndrome cohort
Other indications for Ropivacaine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Osteoarthritis, Hip | — | P4 | BBB · 76 |
| Post-Operative Pain, Non-Human Animal | — | P4 | BBB · 76 |
| Cerebral Palsy | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ropivacaine in Chronic Pain Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ropivacaine-chronic-pain-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →